114 related articles for article (PubMed ID: 38593055)
1. Evaluation of
Karadağ A; Dirican E; Özmerdiven ÇG; Özen A; Ayan S; Kabadere S
Nucleosides Nucleotides Nucleic Acids; 2024 Apr; ():1-12. PubMed ID: 38593055
[TBL] [Abstract][Full Text] [Related]
2. LncRNA BRCAT54 is downregulated and inhibits cancer cell proliferation by downregulating miR-130b-3p through methylation in prostate cancer.
Liang H; Lu Y; Huang X; Ye T
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23552. PubMed ID: 37888834
[TBL] [Abstract][Full Text] [Related]
3. Serum Levels of miR-223-3p and miR-223-5p in Prostate Diseases.
Dülgeroğlu Y; Eroğlu O
Microrna; 2020; 9(4):303-309. PubMed ID: 33155933
[TBL] [Abstract][Full Text] [Related]
4. MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia.
Abramovic I; Vrhovec B; Skara L; Vrtaric A; Nikolac Gabaj N; Kulis T; Stimac G; Ljiljak D; Ruzic B; Kastelan Z; Kruslin B; Bulic-Jakus F; Ulamec M; Katusic-Bojanac A; Sincic N
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922968
[TBL] [Abstract][Full Text] [Related]
5. Identification of MicroRNAs as Viable Aggressiveness Biomarkers for Prostate Cancer.
Martínez-González LJ; Sánchez-Conde V; González-Cabezuelo JM; Antunez-Rodríguez A; Andrés-León E; Robles-Fernandez I; Lorente JA; Vázquez-Alonso F; Alvarez-Cubero MJ
Biomedicines; 2021 Jun; 9(6):. PubMed ID: 34198846
[TBL] [Abstract][Full Text] [Related]
6. Telomerase Activity and Telomere Length in Human Benign Prostatic Hyperplasia Stem-like Cells and Their Progeny Implies the Existence of Distinct Basal and Luminal Cell Lineages.
Rane JK; Greener S; Frame FM; Mann VM; Simms MS; Collins AT; Berney DM; Maitland NJ
Eur Urol; 2016 Apr; 69(4):551-554. PubMed ID: 26455356
[TBL] [Abstract][Full Text] [Related]
7. An integrated view of the role of miR-130b/301b miRNA cluster in prostate cancer.
Fort RS; Mathó C; Oliveira-Rizzo C; Garat B; Sotelo-Silveira JR; Duhagon MA
Exp Hematol Oncol; 2018; 7():10. PubMed ID: 29744254
[TBL] [Abstract][Full Text] [Related]
8. miR-96-5p, miR-134-5p, miR-181b-5p and miR-200b-3p heterogenous expression in sites of prostate cancer versus benign prostate hyperplasia-archival samples study.
Pełka K; Klicka K; Grzywa TM; Gondek A; Marczewska JM; Garbicz F; Szczepaniak K; Paskal W; Włodarski PK
Histochem Cell Biol; 2021 Mar; 155(3):423-433. PubMed ID: 33331954
[TBL] [Abstract][Full Text] [Related]
9. Circulating plasma miR222-3P status and its potential diagnostic performance in prostate cancer.
Heydari Z; Moudi E; Sadeghi F; Hajiahmadi M; Rezatabar S; Neamati N; Parsian H
J Gene Med; 2022 Dec; 24(12):e3459. PubMed ID: 36279183
[TBL] [Abstract][Full Text] [Related]
10. miR-130b duplex (miR-130b-3p/miR-130b-5p) negatively regulates goat intramuscular preadipocyte lipid droplets accumulation by inhibiting Krüppel-like factor 3 expression.
Li Y; He C; Ran L; Wang Y; Xiong Y; Wang Y; Zhu J; Lin Y
J Anim Sci; 2023 Jan; 101():. PubMed ID: 37279650
[TBL] [Abstract][Full Text] [Related]
11. Patients with benign prostatic hyperplasia show shorter leukocyte telomere length but no association with telomerase gene polymorphisms in Han Chinese males.
Cheng G; Dai M; Xin Q; Wang L; Kong F; Xu D
Int J Clin Exp Pathol; 2020; 13(8):2123-2129. PubMed ID: 32922609
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
[TBL] [Abstract][Full Text] [Related]
13. [Prostate-specific antigen and telomerase in prostatic cancers].
Poliakovskiĭ KA; Glukhov AI; zezerov EG; Varshavskiĭ VA; Vinarov AZ; Amosov AV; Rapoport LM; Aliaev IuG; Severin ES; Zimnik OV
Klin Lab Diagn; 2008 Dec; (12):37-8. PubMed ID: 19198276
[TBL] [Abstract][Full Text] [Related]
14. Genome-Wide Screen of miRNAs and Targeting mRNAs Reveals the Negatively Regulatory Effect of miR-130b-3p on PTEN by PI3K and Integrin β1 Signaling Pathways in Bladder Carcinoma.
Lv M; Zhong Z; Chi H; Huang M; Jiang R; Chen J
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28042869
[TBL] [Abstract][Full Text] [Related]
15. Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role.
Cochetti G; Poli G; Guelfi G; Boni A; Egidi MG; Mearini E
Onco Targets Ther; 2016; 9():7545-7553. PubMed ID: 28008272
[TBL] [Abstract][Full Text] [Related]
16. Telomerase activity: a prevalent marker of malignant human prostate tissue.
Sommerfeld HJ; Meeker AK; Piatyszek MA; Bova GS; Shay JW; Coffey DS
Cancer Res; 1996 Jan; 56(1):218-22. PubMed ID: 8548767
[TBL] [Abstract][Full Text] [Related]
17. Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer.
McDonald AC; Vira M; Shen J; Sanda M; Raman JD; Liao J; Patil D; Taioli E
Prostate; 2018 May; 78(6):411-418. PubMed ID: 29383739
[TBL] [Abstract][Full Text] [Related]
18. Profiling of circulating microRNAs for prostate cancer biomarker discovery.
Haldrup C; Kosaka N; Ochiya T; Borre M; Høyer S; Orntoft TF; Sorensen KD
Drug Deliv Transl Res; 2014 Feb; 4(1):19-30. PubMed ID: 25786615
[TBL] [Abstract][Full Text] [Related]
19. MiR-130b-3p promotes colorectal cancer progression by targeting CHD9.
Song D; Zhang Q; Zhang H; Zhan L; Sun X
Cell Cycle; 2022; 21(6):585-601. PubMed ID: 35100082
[TBL] [Abstract][Full Text] [Related]
20. Increased oncogenic microRNA-18a expression in the peripheral blood of patients with prostate cancer: A potential novel non-invasive biomarker.
Al-Kafaji G; Al-Naieb ZT; Bakhiet M
Oncol Lett; 2016 Feb; 11(2):1201-1206. PubMed ID: 26893719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
